SPPI · Spectrum Pharmaceuticals
Acquired Company
On July 31, 2023 (the “Closing Date”), pursuant to the terms and conditions set forth in the Merger Agreement, Merger Sub was merged with and into Spectrum, with Spectrum surviving the Merger as a wholly-owned subsidiary of Assertio.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$1.03
Open
$1.03
Volume
N/A
Day Range
$1.03 - $1.03
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
9.68%
Institutional Own.
22.70%
Qtr Updated
Sep 30th 2024